CD274 and cancer: Given the rationale that cancer cells actively avoid host immune response by expressing ligands specific to PD-1 receptors of the T-lymphocytes, which results in a downregulation of cell cytotoxic activity, it is assumed that PD-L1-positive tumors are more likely to respond to PD-L1 inhibition than PD-L1-negative tumors.